Abionyx Pharma SA

ABL Texcell Diagnostics has raised its full-year 2026 revenue guidance to between €13.5 million and €14.0 million, up from the €12.265 million target it announced on 1 June 2026. The revised range represents an increase of 10.1% to 14.1% over the initial target and year-on-year growth of 94.2% to 101.4% compared with 2025 revenue of €6.950 million. The company said the new guidance reflects first-half performance, business activity seen since the start of the second half and the expected contribution from the TEXCELL activities and assets since their acquisition. For the first half of 2026, ABL Texcell Diagnostics reported revenue of €5.415 million, up 90.0%, EBITDA of €1.315 million and an EBITDA margin of 24.3%, with EBIT of €1.115 million and net profit of €1.280 million. The Évry Commercial Court selected the company on 21 July 2026 to acquire TEXCELL's activities and assets, a deal that includes continued operations at the Genopole site in Évry-Courcouronnes and the integration of 29 employees, and the guidance counts only the acquired activities from their effective transfer date. The company also cited its first publicly announced partnership with ABIONYX Pharma for viral safety and viral clearance studies on CER-001, and shareholders approved the new corporate name ABL Texcell Diagnostics at an Extraordinary General Meeting on 17 September 2026.